Beam Therapeutics INC Form 4 insider transactions

Bethany J. Cavanagh, SVP, Finance and Treasurer of Beam Therapeutics Inc., sold 6,287 shares of common stock at $35 per share on February 18, 2025, under a pre-arranged 10b5-1 trading plan.

Christine Bellon, Chief Legal Officer of Beam Therapeutics, executed stock options and sold a portion of the acquired shares on February 14, 2025, according to a recent SEC Form 4 filing.

Christine Bellon, Chief Legal Officer of Beam Therapeutics Inc., acquired stock options for 40,000 shares on January 31, 2025.

Giuseppe Ciaramella, President of Beam Therapeutics Inc., acquired 70,000 stock options on January 31, 2025, according to a Form 4 filing.

Amy Simon, Chief Medical Officer of Beam Therapeutics Inc., was granted stock options to purchase 55,000 shares of common stock.

CEO John M. Evans of Beam Therapeutics sold shares of common stock and acquired stock options according to a recent SEC Form 4 filing.

Bethany J Cavanagh, SVP, Finance and Treasurer at Beam Therapeutics, reports the acquisition of a stock option for 20,000 shares of common stock.

Christine Bellon, Chief Legal Officer of Beam Therapeutics, sold 1,241 shares of common stock to cover tax obligations related to vesting restricted stock units.

Bethany J. Cavanagh, SVP, Finance and Treasurer at Beam Therapeutics, sold 1,117 shares of common stock to cover tax obligations related to vesting restricted stock units.

Beam Therapeutics' Chief Financial Officer, Sravan Kumar Emany, was granted 80,000 restricted stock units and options to purchase 160,000 shares of common stock on December 31, 2024.

Giuseppe Ciaramella, President of Beam Therapeutics, exercised stock options and disposed of 53,500 shares of common stock on December 17, 2024.

A Beam Therapeutics director, Chirfi Guindo, acquired 39,086 stock options on December 2, 2024, at an exercise price of $28.30.

Giuseppe Ciaramella, President of Beam Therapeutics, sold 51,110 shares of common stock on November 6, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Giuseppe Ciaramella, President of Beam Therapeutics, executed stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Christine Bellon, Chief Legal Officer of Beam Therapeutics, sold 385 shares of common stock to cover tax withholding obligations.

Bethany J Cavanagh, SVP, Finance and Treasurer of Beam Therapeutics, reports acquisition of restricted stock units and sale of common stock to cover tax obligations.

Beam Therapeutics CEO John M. Evans sold 60,000 shares of common stock on September 30, 2024, at a weighted average price of $24.6004.

Bethany J Cavanagh, SVP, Finance and Treasurer of Beam Therapeutics, reports the acquisition of 5,000 stock options.

Amy Simon, Chief Medical Officer of Beam Therapeutics, sold shares of common stock to cover tax withholding obligations and pursuant to a pre-arranged trading plan.

Beam Therapeutics CEO John M. Evans sold 60,000 shares of common stock on June 27, 2024, at a weighted average price of $24.5026 per share, according to a Form 4 filing with the SEC.

Director Christi Shaw reported the acquisition of stock options in Beam Therapeutics, according to a Form 4 filing.

Director John Maraganore reports receiving a stock option grant from Beam Therapeutics.

Director Carole Ho of Beam Therapeutics Inc. reports the acquisition of stock options.

Director Graham K Cooper acquired 23,114 stock options in Beam Therapeutics Inc. on June 5, 2024.

Kathleen Walsh, a director at Beam Therapeutics, reported the acquisition of stock options on June 5, 2024.

Director Mark Fishman acquired 23,114 stock options in Beam Therapeutics Inc. on June 5, 2024.

Terry-Ann Burrell, CFO of Beam Therapeutics, reports the acquisition of stock options and restricted stock units.

Amy Simon, Chief Medical Officer of Beam Therapeutics, sold shares of common stock on April 1st and 2nd, 2024, to cover tax withholding obligations.

Christine Bellon, Chief Legal Officer of Beam Therapeutics, sold 3,401 shares of common stock on April 1, 2024, to cover tax withholding obligations.

Beam Therapeutics' CFO, Terry-Ann Burrell, sold shares to cover tax obligations related to vesting restricted stock units.